Clicky

Mirati Ther(26M)

Description: Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.


Keywords: Medicine Cancer Clinical Medicine Tyrosine Kinase Receptors Kras Mek Inhibitor G12 C

Home Page: www.mirati.com

3545 Cray Court
San Diego, CA 92121
United States
Phone: 858 332 3410


Officers

Name Title
Mr. David D. Meek CEO & Director
Dr. Charles M. Baum M.D., Ph.D. Founder, Pres, Head of R&D and Director
Dr. James G. Christensen Ph.D. Exec. VP & Chief Scientific Officer
Mr. Benjamin J. Hickey M.B.A. Chief Commercial Officer
Ms. Laurie D. Stelzer Chief Financial Officer
Ms. Reena R. Desai Chief Legal Officer & Corp. Sec.
Mr. Michael E. Paolucci Chief People Officer
Dr. Kelly Covello Ph.D. VP & Head of Medical Affairs
Mr. Ryan Asay VP & Head of Corp. Affairs
Dr. Alan Bart Sandler M.D. Exec. VP & Chief Medical Officer

Exchange: F

Country: DE

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.1181
Price-to-Sales TTM: 201.8412
IPO Date:
Fiscal Year End: December
Full Time Employees: 413
Back to stocks